Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arch Gynecol Obstet ; 307(3): 927-935, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-35780401

RESUMO

PURPOSE: Uterine sarcoma (US) as a histologically heterogeneous group of tumors is rare and associated with poor prognosis. Prognostic factors based on systematic data collection need to be identified to optimize patients' treatment. METHODS: This unicenter, retrospective cohort study includes 57 patients treated at the University Hospital Freiburg, Germany between 1999 and 2017. Progression-free survival (PFS) and overall survival (OS) were calculated and visualized in Kaplan-Meier curves. Prognostic factors were identified using log-rank test and Cox regression. RESULTS: 44 Leiomyosarcoma (LMS), 7 low-grade endometrial stromal sarcoma (LG-ESS), 4 high-grade ESS and 2 undifferentiated US patients were identified. The median age at time of diagnosis was 51.0 years (range 18-83). The median follow-up time was 35 months. PFS for the total cohort was 14.0 (95%-Confidence-Interval (CI) 9.7-18.3) and OS 36.0 months (95%-CI 22.1-49.9). Tumor pathology was prognostically significant for OS with LG-ESS being the most favorable (mean OS 150.3 months). In the multivariate analysis, patients over 52 years showed a four times higher risk for tumor recurrence (hazard ratio (HR) 4.4; 95%-CI 1.5-12.9). Progesterone receptor negativity was associated with a two times higher risk for death (HR 2.8; 95%-CI 1.0-7.5). For LMS patients age ≥ 52 years (p = 0.04), clear surgical margins (p = 0.01), FIGO stage (p = 0.01) and no application of chemotherapy (p = 0.02) were statistically significant factors for OS. CONCLUSION: Tumor histology, age at time of diagnosis and progesterone receptor status were prognostic factors for US. Unfavorable OS in LMS patients was associated with advanced FIGO stage, suboptimal cytoreduction and application of chemotherapy.


Assuntos
Neoplasias do Endométrio , Tumores do Estroma Endometrial , Leiomiossarcoma , Neoplasias Pélvicas , Sarcoma do Estroma Endometrial , Sarcoma , Neoplasias Uterinas , Feminino , Humanos , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Prognóstico , Estudos Retrospectivos , Receptores de Progesterona , Recidiva Local de Neoplasia/patologia , Sarcoma/patologia , Neoplasias Uterinas/patologia , Leiomiossarcoma/cirurgia , Sarcoma do Estroma Endometrial/patologia , Neoplasias do Endométrio/patologia , Taxa de Sobrevida
2.
Ann Surg Oncol ; 25(13): 3966-3973, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30238246

RESUMO

BACKGROUND: Despite the complexity of endometrial cancer (EC) tumor biology, treatment decisions are still mainly based on the post-surgical International Federation of Gynecology and Obstetrics (FIGO) stage. Prediction models considering more prognostic factors may represent a better risk assessment than FIGO stage alone. We tested the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram for the prediction of overall survival (OS) in a German EC population. METHODS: Overall, 454 EC patients (322 type I and 132 type II) who received primary surgical treatment at our department between 1991 and 2011 were included in the analysis with a dataset of 68 covariates. Predicted OS was calculated using the online MSKCC nomogram and compared with the observed survival in our population. To estimate the discriminatory power, the concordance probabilities were calculated using the concordance probability estimate (CPE). Receiver operating characteristic curves were created and the area under the curve (AUC) values compared between predicted and actual OS. RESULTS: After a mean follow-up of 183 months, 211 patients were reported dead (47%). Mean OS for all stages was 101 months (standard deviation 66.7 months). The 2009 FIGO system showed an AUC value of 0.6 and a CPE of 0.63, while the 3-year OS prediction of the MSKCC nomogram showed an AUC value of 0.8 and a CPE of 0.77. CONCLUSION: This external validation of the MSKCC nomogram showed better discrimination and calibration values than the conventional FIGO classification system. The nomogram was externally validated and can serve as a tool for better risk-adapted treatment decisions and patient stratification, e.g. in clinical trials.


Assuntos
Adenocarcinoma/secundário , Adenocarcinoma/cirurgia , Neoplasias do Endométrio/patologia , Neoplasias do Endométrio/cirurgia , Nomogramas , Idoso , Área Sob a Curva , Calibragem , Feminino , Previsões/métodos , Humanos , Metástase Linfática , Pessoa de Meia-Idade , Gradação de Tumores , Estadiamento de Neoplasias , Intervalo Livre de Progressão , Curva ROC , Medição de Risco/métodos , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...